Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. announced the renewal of the Neptunus Group Sales Framework Agreement with Shenzhen Neptunus Group Company Limited. Under the new agreement, the company will continue to sell certain self-manufactured or distributed products, including pharmaceutical products, healthcare food products, and medical devices, to the Neptunus Group for the period up to 31 December 2028. The announcement also sets out the proposed 2028 sales cap, representing the estimated maximum aggregate sales amount for that year. The agreement constitutes a continuing connected transaction, and certain directors of the company hold positions within the Neptunus Group and its subsidiaries. The renewal and terms of the agreement are subject to relevant regulatory requirements and independent shareholder approval.